NCT05185739
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05185739
Title Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1)
Acronym PRIMER-1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field